Top Abstract Purchase Related
Home
>
Node
>
Subnode

Radiologic Improvement of juvenile idiopathic arthritis-enthesitis-related arthritis following anti-tumor necrosis factor-alpha blockade with etanercept

Tse, S.M.L.; Laxer, R.M.; Babyn, P.S.; Doria, A.S.

Journal of Rheumatology 33(6): 1186-1188

2006

ISSN/ISBN: 0315-162X
PMID: 16755667
Document Number: 602763
Children with juvenile spondyloarthropathy, classified as enthesitis-related arthritis (ERA) under the International League of Associations for Rheumatology classification of juvenile idiopathic arthritis, usually experience both arthritis and enthesitis. Treatment with anti-tumor necrosis factor-alpha (TNF-alpha) agents has resulted in dramatic clinical improvement. Radiologic imaging methods useful in the detection, diagnosis, and grading of arthritis and enthesitis include magnetic resonance imaging and ultrasonography. We describe the serial radiologic improvements of arthritis and enthesitis in a child with ERA in response to treatment with the anti-TNF-alpha agent etanercept.

Document emailed within 1 workday
Secure & encrypted payments

Macías, I.; García-Pérez, S.; Ruiz-Tudela, M.; Medina, F.ín.; Chozas, N.ás.; Girón-González, J.é A. 2005: Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-a blockade in patients with rheumatoid arthritis Journal of Rheumatology 32(11): 2102-2108
Feldmann, M.; Brennan, F.; Paleolog, E.; Taylor, P.; Maini, R.N. 1997: Anti-tumor necrosis factor alpha therapy of rheumatoid arthritis. Mechanism of action European Cytokine Network 8(3): 297-300
Van Lieshout, A.W.T.; Creemers, M.C.W.; Radstake, T.R.D.J.; Elving, L.D.; van Riel, P.L.C.M. 2008: Graves' disease in a patient with rheumatoid arthritis during treatment with anti-tumor necrosis factor-alpha Journal of Rheumatology 35(5): 938-939
Furst, D.E.; Schiff, M.H.; Fleischmann, R.M.; Strand, V.; Birbara, C.A.; Compagnone, D.; Fischkoff, S.A.; Chartash, E.K. 2003: Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis) Journal of Rheumatology 30(12): 2563-2571
Antoni, C.; Kalden, J.R. 1999: Combination therapy of the chimeric monoclonal anti-tumor necrosis factor alpha antibody (infliximab) with methotrexate in patients with rheumatoid arthritis Clinical and Experimental Rheumatology 17(6 Suppl 18: S73-S77
Pratsidou-Gertsi, P.; Trachana, M.; Pardalos, G.; Kanakoudi-Tsakalidou, F. 2010: A follow-up study of patients with juvenile idiopathic arthritis who discontinued etanercept due to disease remission Clinical and Experimental Rheumatology 28(6): 919-922
Vojvodich, P.Fernandez.; Hansen, J.B.; Andersson, U.; Sävendahl, L.; Hagelberg, S. 2007: Etanercept treatment improves longitudinal growth in prepubertal children with juvenile idiopathic arthritis Journal of Rheumatology 34(12): 2481-2485
Tsybul'ko, S.V.; Baranov, A.A.; Borodin, A.G.; Korshunov, N.I.; Kirdianov, S.Iu. 2001: Tumor necrosis factor-alpha and kidney damage in rheumatoid arthritis Terapevticheskii Arkhiv 73(5): 8-11
De Filippis, L.; Caliri, A.; Anghelone, S.; Scibilia, G.; Lo Gullo, R.; Bagnato, G. 2006: Improving outcomes in tumour necrosis factor a treatment: comparison of the efficacy of the tumour necrosis factor a blocking agents etanercept and infliximab in patients with active rheumatoid arthritis Panminerva Medica 48(2): 129-135
Dayer, J.-M. 2002: Interleukin 1 or tumor necrosis factor-alpha: which is the real target in rheumatoid arthritis? Journal of Rheumatology. Suppl 65: 10-15
Kinouchi, R.; Hirokawa, H.; Igarashi, S.; Fukui, K.; Hirano, Y.; Takai, Y.; Yoshida, A. 2007: A case of panuveitis with optic disc neovascularization associated with juvenile idiopathic arthritis which progressed during a clinical trial of etanercept Nippon Ganka Gakkai Zasshi 111(12): 970-975
Fabris, M.; Di Poi, E.; D'Elia, A.; Damante, G.; Sinigaglia, L.; Ferraccioli, G. 2002: Tumor necrosis factor-alpha gene polymorphism in severe and mild-moderate rheumatoid arthritis Journal of Rheumatology 29(1): 29-33
Straub, R.H.; Härle, P.; Atzeni, F.; Weidler, C.; Cutolo, M.; Sarzi-Puttini, P. 2005: Sex hormone concentrations in patients with rheumatoid arthritis are not normalized during 12 weeks of anti-tumor necrosis factor therapy Journal of Rheumatology 32(7): 1253-1258
Jin, D.; Tie, N.; Liu, J.; Zhao, L.; Hao, D.; Zhao, Y. 2015: Investigation of the risk of hepatitis B virus reactivation in arthritis patients undergoing anti-tumour necrosis factor alpha therapy Zhonghua Nei Ke Za Zhi 54(4): 313-316
Ansell, B.M. 1999: Chlorambucil therapy in juvenile chronic arthritis (juvenile idiopathic arthritis) Journal of Rheumatology 26(4): 765-766
Pachot, A.; Arnaud, Béatrice.; Marrote, H.; Cazalis, M-Angélique.; Diasparra, J.; Gouraud, A.; Mougin, B.; Miossec, P. 2007: Increased tumor necrosis factor-alpha mRNA expression in whole blood from patients with rheumatoid arthritis: reduction after infliximab treatment does not predict response Journal of Rheumatology 34(11): 2158-2161
Bendtzen, K.; Hansen, P.R.; Rieneck, K. 2004: Spironolactone inhibits production of proinflammatory cytokines, including tumor necrosis factor-alpha and interferon-gamma and has potential effect in the treatment of arthritis Ugeskrift for Laeger 166(37): 3203-3207
Rémy, A.; Avouac, J.; Gossec, L.; Combe, B. 2011: Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis Clinical and Experimental Rheumatology 29(1): 96-103
Dombrecht, E.J.; Aerts, N.E.; Schuerwegh, A.J.; Hagendorens, M.M.; Ebo, D.G.; Van Offel, J.F.; Bridts, C.H.; Stevens, W.J.; De Clerck, L.S. 2006: Influence of anti-tumor necrosis factor therapy (Adalimumab) on regulatory T cells and dendritic cells in rheumatoid arthritis Clinical and Experimental Rheumatology 24(1): 31-37
Dekker, L.; Armbrust, W.; Rademaker, C.M.A.; Prakken, B.; Kuis, W.; Wulffraat, N.M. 2004: Safety of anti-TNFalpha therapy in children with juvenile idiopathic arthritis Clinical and Experimental Rheumatology 22(2): 252-258